Linda Rubinstein joins Alector as interim CFO. A partner of FLG Partners, a CFO services firm,
Linda brings more than 30 years of operational, financial, and capital markets experience.

Among her other CFO, interim CFO and other consulting roles have included Apexigen,
RenovoRx, ArmaGen, Five Prime Therapeutics, Kezar Life Sciences, EpiBiome, Tunitas, True
North Therapeutics, Retrotope, PaxVax, iPierian (acquired by Bristol-Myers Squibb), Ingenuity
(acquired by QIAGEN), and Solexa (acquired by Illumina). As a CFO, Linda has led the finance
functions at research- and commercial-stage life sciences companies, successfully completed
financing and M&A transactions, and contributed to operations and strategy. Earlier in her
career, Linda served as Vice President of Finance for ChemoCentryx.

Linda began her career as an investment banker, most recently as Senior Vice President of
Lehman Brothers’ Global Healthcare Investment Banking Group. As an investment banker,
Linda completed over 30 transactions, raising over $5 billion in capital for companies.
Linda earned her Bachelor and Master’s degrees in Economics from the University of California,
Los Angeles.